Concepedia
Statistics
Publications
2
Citations
62
H-Index
Active since
2023
Affiliations
Vifor Pharma (United States)(Current)
Dana-Farber Cancer Institute
Sun Yat-sen University Cancer Center
Suzhou Thermal Engineering Research Institute
Sun Yat-sen University
Eric Liang is an author at Vifor Pharma (United States) specializing in chemotherapy, pharmacology, and bcl-2 inhibition.
Publications per year
2023–2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Sikander Ailawadhi, Zi Chen, Bo Huang et al. · Clinical Cancer Research · 2023 · 38 citations · Full text
Medicine, Oncology, Pharmacology +17
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Nehal J. Lakhani, Drew Rasco, Hengbang Wang et al. · Clinical Cancer Research · 2023 · 24 citations
Medicine, Oncology, Pharmacology +16
1–2 of 2